Who
Jacqueline Zummo
Chief R&D Officer
Company insider
Files Form 4 as: Chief R&D Officer, Protara Therapeutics.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $346K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Jan 2020
- Last trade
- 8 Apr 2026
- Last filed
- 9 Apr 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Apr 2026filed 9 Apr 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,1241,134 at $5.40 | filing |
| 8 Apr 2026filed 9 Apr 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,1241,134 at $5.40 | filing |
| 1 Apr 2026filed 2 Apr 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K22,598 at $5.26 | filing |
| 1 Apr 2026filed 2 Apr 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K22,598 at $5.26 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $25K3,724 at $6.67 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $25K3,724 at $6.67 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $37K6,578 at $5.60 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $37K6,578 at $5.60 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Sold | $96K21,224 at $4.53 | filing |
| 24 Jan 2025filed 28 Jan 2025 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —146,000 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,500 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $31K6,554 at $4.76 | filing |
| 3 Jan 2025filed 7 Jan 2025 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $13K2,157 at $6.14 | filing |
| 19 Jan 2024filed 23 Jan 2024 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,000 at $0.00 | filing |
| 19 Jan 2024filed 23 Jan 2024 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 19 Jan 2024filed 23 Jan 2024 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,8243,049 at $1.91 | filing |
News
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 5.3% – Here's WhyTARA · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Jacqueline Zummo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.